AstraZeneca PLC (AZN)vsInnoviva Inc (INVA)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
INVA
Innoviva Inc
$22.99
-0.26%
HEALTHCARE · Cap: $1.71B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 14180% more annual revenue ($58.74B vs $411.33M). INVA leads profitability with a 65.9% profit margin vs 17.4%. INVA appears more attractively valued with a PEG of 0.35. INVA earns a higher WallStSmart Score of 84/100 (A-).
AZN
Buy64
out of 100
Grade: C+
INVA
Exceptional Buy84
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for INVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 66 of every $100 in revenue as profit
Strong operational efficiency at 34.7%
Earnings expanding 590.0% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : INVA
The strongest argument for INVA centers on PEG Ratio, P/E Ratio, Price/Book. Profitability is solid with margins at 65.9% and operating margin at 34.7%. Revenue growth of 24.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : INVA
The primary concerns for INVA are Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while INVA is a growth play — different risk/reward profiles.
INVA carries more volatility with a beta of 0.40 — expect wider price swings.
INVA is growing revenue faster at 24.8% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
INVA scores higher overall (84/100 vs 64/100), backed by strong 65.9% margins and 24.8% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Innoviva Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?